Organic CompoundsA composition comprising, separately or together: a component (A) that is an adenosine A2a receptor agonist as defined in the specification; and a component (B) that is one or more compounds selected from: (i) a corticosteroid, (ii) a beta-2 adrenoceptor agonist, (iii) an antimuscarinic agent, (iv) an A2B antagonist, (v) an antihistamine, (vi) a caspase inhibitor, (vii) an ENaC inhibitor, (viii) an LTB4 antagonist, (ix) an LTD4 antagonist, (x) a serine protease inhibitor, (xi) a PDE4 inhibitor and (xii) a dual-acting beta-2 adrenoceptor agonist/muscarinic antagonist, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.A composition comprising, separately or together (A) a compound selected from: ((1S,2R,3S,4R)-4-{6-(2,2-Diphenyl-ethylamino)-2-[(S)-3-(3-pyridin-3-yl-ureido)-pyrrolidin-1-yl]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-carbamic acid methyl ester; ((1S,2R,3S,4R)-4-{6-(2,2-Diphenyl-ethylamino)-2-[(R)-3-(3-pyridin-3-yl-ureido)-pyrrolidin-1-yl]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-carbamic acid methyl ester; Cyclopropanecarboxylic acid ((1S,2R,3S,4R)-4-{6-(2,2-diphenyl-ethylamino)-2-[(R)-3-(3-pyridin-3-yl-ureido)-pyrrolidin-1-yl]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-amide; N-((1S,2R,3S,4R)-4-{6-(2,2-Diphenyl-ethylamino)-2-[(R)-3-(3-pyridin-2-ylmethyl-ureido)-pyrrolidin-1-yl]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-propionamide trifluoroacetate; N-[(1S,2R,3S,4R)-4-(6-((S)-1-Benzyl-2-hydroxy-ethylamino)-2-{(R)-3-[3-(4-sulfamoyl-phenyl)-ureido]-pyrrolidin-1-yl}-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-2-hydroxy-acetamide; [(1S,2R,3S,4R)-4-(6-(2,2-Diphenyl-ethylamino)-2-{(R)-3-[3-(3-sulfamoyl-phenyl)-ureido]-pyrrolidin-1-yl}-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-carbamic acid methyl ester; N,N′-(1S,1S′,2R,2R′,3S,3S′,4R,4R′)-4,4′-((S)-2,2′-((3R3′R)-3,3′-carbonylbis(azaniediyl)bis(pyrrolidine-3,1-diyl))bis(6-((S)-1-hydroxy-3-phenylpropan-2-ylamino)-9H-purine-9,2diyl))bis(2,3-dihydroxycyclopentane-4,1-diyl)bis(2-hydroxyacetamide); and N,N-(1S,1S′,2R,2R′,3S,3S′,4R,4R′)-4,4′-(6,6′-(1R,4R)-cyclohexane-1,4-diylbis(azanediyl)bis(2-(2-(1-methyl-1Himidazol-4-yl)ethylamino)-9H-purine-9,6-diyl))bis(2,3-dihydroxycyclopentane-4,1-diyl)bis(2-hydroxyacetamide), in free or salt or solvate form; and (B) one or more compounds selected from: (i) a corticosteroid, (ii) a beta-2 adrenoceptor agonist, (iii) an antimuscarinic agent, (iv) an A2B antagonist, (v) an antihistamine, (vi) a caspase inhibitor, (vii) an ENaC inhibitor, (viii) an LTB4 antagonist, (ix) an LTD4 antagonist, (x) a serine protease inhibitor, (xi) a PDE4 inhibitor and (xi) a dual-acting beta-2 adrenoceptor agonist/muscarinic antagonist; for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
퓨린 유도체 및 다른 화합물을 포함하는 조합물, 및 염증성 및 폐쇄성 기도 질환의 치료를 위한 그의 용도본 발명은 염증성 또는 폐쇄성 기도 질환의 치료에서 동시 투여, 순차적 투여 또는 개별적 투여를 위한, 명세서에서 정의된 것과 같은 아데노신 A2a 수용체 효능제인 성분 (A); 및 (i) 코르티코스테로이드, (ii) 베타-2 아드레날린 수용체 효능제, (iii) 항무스카린 작용제, (iv) A2B 길항제, (v) 항히스타민제, (vi) 카스파제 억제제, (vii) ENaC 억제제, (viii) LTB4 길항제, (ix) LTD4 길항제, (x) 세린 프로테아제 억제제, (xi) PDE4 억제제 및 (xii) 이중-작용 베타-2 아드레날린 수용체 효능제/무스카린 길항제로부터 선택되는 하나 이상의 화합물인 성분 (B)를 개별적으로 또는 함께 포함하는 의약에 관한 것이다.(A) 유리 형태 또는 염 형태 또는 용매화물 형태의,((1S,2R,3S,4R)-4-{6-(2,2-디페닐-에틸아미노)-2-[(S)-3-(3-피리딘-3-일-우레이도)-피롤리딘-1-일]-퓨린-9-일}-2,3-디히드록시-시클로펜틸)-카르밤산 메틸 에스테르;((1S,2R,3S,4R)-4-{6-(2,2-디페닐-에틸아미노)-2-[(R)-3-(3-피리딘-3-일-우레이도)-피롤리딘-1-일]-퓨린-9-일}-2,3-디히드록시-시클로펜틸)-카르밤산 메틸 에스테르;시클로프로판카르복실산 ((1S,2R,3S,4R)-4-{6-(2,2-디페닐-에틸아미노)-2-[(R)-3-(3-피리딘-3-일-우레이도)-피롤리딘-1-일]-퓨린-9-일}-2,3-디히드록시-시클로펜틸)-아미드;N-((1S,2R,3S,4R)-4-{6-(2,2-디페닐-에틸아미노)-2-[(R)-3-(3-피리딘-2-일메틸-우레이도)-피롤리딘-1-일]-퓨린-9-일}-2,3-디히드록시-시클로펜틸)-프로피온아미드 트리플루오로아세테이트;N-[(1S,2R,3S,4R)-4-(6-((S)-1-벤질-2-히드록시-에틸아미노)-2-{(R)-3-[3-(4-술파모일-페닐)-우레이도]-피롤리딘-1-일}-퓨린-9-일)-2,3-디히드록시-시클로펜틸]-2-히드록시-아세트아미드;[(1S,2R,3S,4R)-4-(6-(2,2-디페닐-에틸아미노)-2-{(R)-3-[3-(3-술파모일-페닐)-우레이도]-피롤리딘-1-일}-퓨린-9-일)-2,3-디히드록시-시클로펜틸]-카르밤산 메틸 에스테르;N,N'-(1S,1S',2R,2R',3S,3S',4R,4R')-4,4'-((S)-2,2'-((3R,3'R)-3,3'-카르보닐비스(아잔디일)비스(피롤리딘-3,1-디일))비스(6-((S)-1-히드록시-3-페닐프로판-2-일아미노)-9H-퓨린-9,2-디일))비스(2,3-디히드록시시클로펜탄-4,1-디일)비스(2-히드록시아세트아미드); 및N,N'-(1S,1S',2R,2R',3S,3S',4R,4R')-4,4'-(6,6'-(1R,4R)-시클로헥산-1,4-디일비스(아잔디일)비스(2-(2-(1-메틸-1H-이미다졸-4-일)에틸아미노)-9H-퓨린-9,6-디일))비스(2,3-디히드록시시클로펜탄-4,1-디일)비스(2-히드록시아세트아미드)로부터 선택되는 화합물; 및(B)(i) 코르티코스테로이드,(ii) 베타-2 아드레날린 수용체 효능제,(iii) 항무스카린 작용제,(iv) A2B 길항제,(v) 항히스타민제,(vi) 카스파제 억제제,(vii) ENaC 억제제,(viii) LTB4 길항제,(ix) LTD4 길항제,(x) 세린 프로테아제 억제제,(xi) PDE4 억제제 및(xi) 이중-작용 베타-2 아드레날린 수용체 효능제/무스카린 길항제로부터 선택되는 하나 이상의 화합물을 개별적으로 또는 함께 포함하는, 염증성 또는 폐쇄성 기도 질환의 치료에서 동시 투여, 순차적 투여 또는 개별적 투여를 위한 의약.